Buprecare

Main information

  • Trade name:
  • Buprecare 0.3 mg/ml Solution for Injection for Dogs and Cats
  • Pharmaceutical form:
  • Solution for injection
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • Buprecare 0.3 mg/ml Solution for Injection for Dogs and Cats
    Ireland
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • buprenorphine
  • Therapeutic area:
  • Cats, Dogs

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • UK/V/0245/001
  • Authorization date:
  • 15-02-2008
  • EU code:
  • UK/V/0245/001
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

Revised:June2013

AN.00507/2012

Page1of6

SUMMARYOFPRODUCTCHARACTERISTICS

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

Buprecare0.3mg/mlSolutionforInjectionforDogsandCats(UK,BE,FR,IE,LU,NL,

ES)

Buprenovet0.3mg/mlSolutionforInjectionforDogsandCats(AT,DE)

2. QUALITATIVEANDQUANTITATIVECOMPOSITION

Activesubstance:

Eachampoulecontains:

Buprenorphine0.3mg/mlasbuprenorphinehydrochloride.

Forafulllistofexcipients,seesection6.1.

3. PHARMACEUTICALFORM

Solutionforinjection.

Clear,colourlesssolution.

4. CLINICALPARTICULARS

4.1Targetspecies

Dogsandcats

4.2Indicationsforuse,specifyingthetargetspecies

Dog

Post-operativeanalgesia.

Potentiationofthesedativeeffectsofcentrally-actingagents.

Cat

Post-operativeanalgesia.

4.3Contraindications

Theproductshouldnotbeusedpre-operativelyforcaesareansection(seeSection4.7).

Donotuseincaseofhypersensitivitytotheactivesubstanceortoanyoftheexcipients.

4.4Specialwarningsforeachtargetspecies

None.

4.5Specialprecautionsforuse

Specialprecautionsforuseinanimals

Revised:June2013

AN.00507/2012

Page2of6

Buprenorphinemayoccasionallycausesignificantrespiratorydepressionand,aswith

otheropioiddrugs,careshouldbetakenwhentreatinganimalswithimpaired

respiratoryfunctionoranimalsthatarereceivingdrugsthatcancauserespiratory

depression.

Buprenorphineshouldbeusedwithcautioninanimalswithimpairedliverfunction,

especiallybiliarytractdisease,asthesubstanceismetabolisedbytheliverandits

intensityanddurationofactionmaybeaffectedinsomeanimals.

Incaseofrenal,cardiacorhepaticdysfunction,orshock,theremaybegreaterrisk

associatedwiththeuseoftheproduct.Thebenefit:riskratioforusingtheproductshould

bemadebytheattendingvet.Safetyhasnotbeenfullyevaluatedinclinically

compromisedcats.

Thesafetyofbuprenorphinehasnotbeendemonstratedinanimalslessthan7weeksof

age,thereforeuseinsuchanimalsshouldbebasedonthebenefit:riskassessmentby

theveterinarian.

Repeatedadministrationearlierthantherecommendedrepeatintervalsuggestedin

Section4.9isnotrecommended.

Theeffectofanopioidonheadinjuryisdependentonthetypeandseverityoftheinjury

andtherespiratorysupportsupplied.Theproductshouldbeusedinaccordancewiththe

benefit:riskassessmentoftheattendingveterinarian.

Specialprecautionstobetakenbythepersonadministeringtheveterinary

medicinalproducttoanimals

Asbuprenorphinehasopioid-likeactivitycareshouldbetakentoavoidaccidentalself-

injection.

Incaseofaccidentalself-injectionoringestion,seekmedicaladviceimmediatelyand

showthepackageleafletorthelabeltothephysician.Naloxoneshouldbeavailablein

caseofaccidentalparenteralexposure.

Followingeyecontaminationorskincontact,washthoroughlywithcoldrunningwater,

seekmedicaladviceifirritationpersists.

4.6Adversereactions(frequencyandseriousness)

Salivation,bradycardia,hypothermia,agitation,dehydrationandmiosiscanoccurinthe

dog,andrarelyhypertensionandtachycardia.

Mydriasisandsignsofeuphoria(excessivepurring,pacing,rubbing)commonlyoccurin

cats,andwillusuallyresolvewithin24hours.

Buprenorphinemayoccasionallycausesignificantrespiratorydepression;referto

section4.5.

Whenusedtoprovideanalgesia,sedationisrarelyseen,butmayoccuratdoselevels

higherthanthoserecommended.

4.7Useduringpregnancy,lactationorlay

Pregnancy:

Revised:June2013

AN.00507/2012

Page3of6

Laboratorystudiesinratshavenotproducedanyevidenceofateratogeniceffect.

However,thesestudieshaveshownpost-implantationlossesandearlyfoetaldeaths.As

reproductivetoxicitystudieshavenotbeenconductedinthetargetspecies,useonly

accordingtothebenefit:riskassessmentbytheresponsibleveterinarian.

Theproductshouldnotbeusedpre-operativelyincasesofcaesareansection,dueto

theriskofrespiratorydepressionintheoffspringperiparturiently,andshouldonlybe

usedpost-operativelywithspecialcare(seesectiononlactationbelow).

Lactation:

Studiesinlactatingratshaveshownthat,afterintramuscularadministrationof

buprenorphine,concentrationsofunchangedbuprenorphineinthemilkequalledor

exceededthatintheplasma.Asitislikelythatbuprenorphinewillbeexcretedinthemilk

ofotherspecies,useisnotrecommendedduringlactation.Useonlyaccordinglyto

benefit:riskassessmentbytheresponsibleveterinarian.

4.8Interactionwithothermedicinalproductsandotherformsofinteraction

Buprenorphinemaycausesomedrowsiness,whichmaybepotentiatedbyother

centrally-actingagents,includingtranquillisers,sedativesandhypnotics.

Thereisevidenceinhumanstoindicatethattherapeuticdosesofbuprenorphinedonot

reducetheanalgesicefficacyofstandarddosesofanopioidagonist,andthatwhen

buprenorphineisemployedwithinthenormaltherapeuticrange,standarddosesof

opioidagonistmaybeadministeredbeforetheeffectsoftheformerhaveendedwithout

compromisinganalgesia.However,itisrecommendedthatbuprenorphineisnotusedin

conjunctionwithmorphineorotheropioid-typeanalgesics,e.g.etorphine,fentanyl,

pethidine,methadone,papaveretumorbutorphanol.

Buprenorphinehasbeenusedwithacepromazine,alphaxalone/alphadalone,atropine,

dexmedetomidine, halothane, isoflurane, ketamine, medetomidine, propofol,

sevoflurane,thiopentoneandxylazine.Whenusedincombinationwithsedatives,

depressiveeffectsonheartrateandrespirationmaybeaugmented.

4.9Amountstobeadministeredandadministrationroute

Forintramuscularuse.

SpeciesPost-OperativeAnalgesia Sedation

Dog 10 –20microgramperkg(0.3–0.6mlper10kg)

repeatedifnecessaryafter3 –4hourswith10

microgramor5 –6hourswith20microgramdoses. 10 –20microgramper

kg(0.3 –0.6mlper10

kg).

Cat 10 –20microgramperkg(0.3–0.6mlper10kg),

repeatedifnecessary,once,after2hours.

Whilesedativeeffectsarepresentby15minutesafteradministration,analgesicactivity

becomesapparentafterapproximately30minutes.Toensurethatanalgesiaispresent

duringsurgeryandimmediatelyonrecovery,theproductshouldbeadministered

preoperativelyaspartofpremedication.

Whenadministeredforpotentiationofsedationoraspartofpremedication,thedoseof

othercentrally-actingagents,suchasacepromazineormedetomidine,shouldbe

reduced.Thereductionwilldependonthedegreeofsedationrequired,theindividual

Revised:June2013

AN.00507/2012

Page4of6

animal,thetypeofotheragentsincludedinpremedicationandhowanaesthesiaistobe

inducedandmaintained.Itmayalsobepossibletoreducetheamountofinhalational

anaestheticused.Animalsadministeredopioidspossessingsedativeandanalgesic

propertiesmayshowvariableresponses.Therefore,theresponsesofindividualanimals

shouldbemonitoredandsubsequentdosesshouldbeadjustedaccordingly.Insome

casesrepeatdosesmayfailtoprovideadditionalanalgesia.Inthesecases,

considerationshouldbegiventousingasuitableinjectableNSAID.

Anappropriatelygraduatedsyringemustbeusedtoallowaccuratedosing.

4.10Overdose(symptoms,emergencyprocedures,antidotes),ifnecessary

Whenadministeredatoverdosetodogs,buprenorphinemaycauselethargy.Atvery

highdoses,bradycardiaandmiosismaybeobserved.

Intoxicologicalstudiesofbuprenorphinehydrochlorideindogs,biliaryhyperplasiawas

observedafteroraladministrationforoneyearatdoselevelsof3.5mg/kg/dayand

above.Biliaryhyperplasiawasnotobservedfollowingdailyintramuscularinjectionof

doselevelsupto2.5mg/kg/dayfor3months.Thisiswellinexcessofanyclinicaldose

regimeninthedog.

Incaseofoverdosage,supportivemeasuresshouldbeinstitutedandifappropriate,

naloxoneorrespiratorystimulantsmaybeused.However,doselevelsmanytimes

higherthanthoseindicatedabovehavebeenusedwithoutserioussideeffects.

Naloxonemaybeofbenefitinreversingreducedrespiratoryrateandrespiratory

stimulantssuchasDoxapramarealsoeffectiveinman.Becauseoftheprolonged

durationofeffectofbuprenorphineincomparisontosuchdrugs,theymayneedtobe

administeredrepeatedlyorbycontinuousinfusion.

Volunteerstudiesinmanhaveindicatedthatopiateantagonistsmaynotfullyreversethe

effectsofbuprenorphine.

Pleasealsorefertosections4.5and4.6ofthisSPC.

4.11Withdrawalperiod(s)

Notapplicable.

5. PHARMACOLOGICALPROPERTIES

Pharmacotherapeuticgroup:Opioidanalgesics,oripavinederivatives

ATCvetcode:QN02AE01

5.1Pharmacodynamicproperties

Insummarybuprenorphineisapotent,long-actinganalgesicactingatopiatereceptors

inthecentralnervoussystem.

Revised:June2013

AN.00507/2012

Page5of6

Buprenorphineexertsitsanalgesiceffectviahighaffinitybindingtovarioussubclasses

ofopiatereceptors,particularlyµ,inthecentralnervoussystem.Atclinicaldoselevels

foranalgesia,buprenorphinedemonstrateshighefficacyandbindstoopiatereceptors

withhighaffinity,suchthatitsdissociationfromthereceptorsiteisslow,as

demonstratedininvitrostudies.Thispropertyofbuprenorphinecouldaccountforits

longerdurationofactivitywhencomparedtomorphine.Incircumstanceswhere

excessiveopiateagonistisalreadyboundtoopiatereceptors,buprenorphinecanexert

anarcoticantagonisticactivityasaconsequenceofitshigh-affinityopiatereceptor

binding,suchthatanantagonisticeffectonmorphineequivalenttonaloxonehasbeen

demonstrated.

5.2Pharmacokineticparticulars

Buprenorphineisrapidlyabsorbedafterintramuscularinjectioninvariousanimal

speciesandman.Thesubstanceishighlylipophilicandthevolumeofdistributionin

bodycompartmentsislarge.Inthecat,pharmacologicaleffectsoccurwithin30minutes

afterinjectionandpeakeffectsareusuallyobservedatabout1 –1.5hours.Following

intramuscularadministrationtocats,themeanterminalhalf-lifewas6.3hoursandthe

clearancewas23ml/kg/min,however,therewasconsiderableinter-catvariabilityin

pharmacokineticparameters.

Norelevantpharmacokineticdataareavailableinthedog.

Combinedpharmacokineticandpharmacodynamicstudiesincatshavedemonstrated

amarkeddelaybetweenplasmaconcentrationsandanalgesiceffect.Plasma

concentrationsofbuprenorphineshouldnotbeusedtoformulateindividualanimal

dosageregimens,whichshouldbedeterminedbymonitoringofthepatient’sresponse.

Themajorrouteofexcretioninallspeciesexcepttherabbit(whereurinaryexcretion

predominates)isthefaeces.BuprenorphineundergoesN-dealkylationandglucuronide

conjugationbytheintestinalwallandtheliveranditsmetabolitesareexcretedviathe

bileintothegastro-intestinaltract.

Intissuedistributionstudiescarriedoutinratsandrhesusmonkeys,thehighest

concentrationsofdrug-relatedmaterialwereobservedinliver,lungandbrain.Peak

levelsoccurredrapidlyanddeclinedtolowlevelsby24hoursafterdosing.

Proteinbindingstudiesinratshaveshownthatbuprenorphineishighlyboundtoplasma

proteins,principallytoalphaandbetaglobulins.

6. PHARMACEUTICALPARTICULARS

6.1Listofexcipients

Glucose,anhydrous

Hydrochloricacid

Waterforinjection

6.2Incompatibilities

Noneknown.

Revised:June2013

AN.00507/2012

Page6of6

6.3Shelflife

Shelf-lifeoftheveterinarymedicinalproductaspackagedforsale:3years.

Theproductdoesnotcontainanantimicrobialpreservative.Useimmediatelyafteropening

theampoule.Anysolutionremaininginanampoulefollowingwithdrawaloftherequired

doseshouldbediscarded.

6.4Specialprecautionsforstorage

Donotstoreabove25

C.

Protectfromlight.

Donotrefrigerateorfreeze.

6.5Natureandcompositionofimmediatepackaging

Presentedin1mlclearTypeIglass,snapampoules,inboxesoffive.

6.6Specialprecautionsforthedisposalofunusedveterinarymedicinal

productorwastematerialsderivedfromtheuseofsuchproducts

Anyunusedveterinarymedicinalproductorwastematerialsderivedfromsuch

veterinarymedicinalproductsshouldbedisposedofinaccordancewithlocal

requirements

7. MARKETINGAUTHORISATIONHOLDER

AnimalcareLimited,

CommonRoad,

Dunnington,

York,YO195RU

UK

8. MARKETINGAUTHORISATIONNUMBER

Vm10347/4024

9. DATEOFFIRSTAUTHORISATION

28May2008

10.DATEOFREVISIONOFTHETEXT

June2013

Approved: 03/06/2013

28-11-2018

Prenoxad 1 mg/mL solution for injection (naloxone hydrochloride)

Prenoxad 1 mg/mL solution for injection (naloxone hydrochloride)

Update - medicine shortage

Therapeutic Goods Administration - Australia

21-9-2018

Pending EC decision:  Buvidal, buprenorphine, Opinion date: 20-Sep-2018

Pending EC decision: Buvidal, buprenorphine, Opinion date: 20-Sep-2018

Europe - EMA - European Medicines Agency

7-9-2018

FDA approves new dosage strength of buprenorphine and naloxone sublingual film as maintenance treatment for opioid dependence

FDA approves new dosage strength of buprenorphine and naloxone sublingual film as maintenance treatment for opioid dependence

FDA approved Cassipa (buprenorphine and naloxone) sublingual film (applied under the tongue) for the maintenance treatment of opioid dependence.

FDA - U.S. Food and Drug Administration

29-8-2018

Risk to human and animal health related to the presence of 4,15‐diacetoxyscirpenol in food and feed

Risk to human and animal health related to the presence of 4,15‐diacetoxyscirpenol in food and feed

Published on: Thu, 16 Aug 2018 00:00:00 +0200 4,15‐Diacetoxyscirpenol (DAS) is a mycotoxin primarily produced by Fusarium fungi and occurring predominantly in cereal grains. As requested by the European Commission, the EFSA Panel on Contaminants in the Food Chain (CONTAM) assessed the risk of DAS to human and animal health related to its presence in food and feed. Very limited information was available on toxicity and on toxicokinetics in experimental and farm animals. Due to the limitations in the avai...

Europe - EFSA - European Food Safety Authority Publications

14-6-2018

FDA approves first generic versions of Suboxone sublingual film, which may increase access to treatment for opioid dependence

FDA approves first generic versions of Suboxone sublingual film, which may increase access to treatment for opioid dependence

: FDA approved the first generic versions of Suboxone (buprenorphine and naloxone) sublingual film (applied under the tongue) for the treatment of opioid dependence.

FDA - U.S. Food and Drug Administration

28-11-2018

Econor (Elanco GmbH)

Econor (Elanco GmbH)

Econor (Active substance: Valnemulin hydrochloride) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)8038 of Wed, 28 Nov 2018 European Medicines Agency (EMA) procedure number: EMEA/V/C/42/T/54

Europe -DG Health and Food Safety

26-11-2018

Wakix (Bioprojet Pharma)

Wakix (Bioprojet Pharma)

Wakix (Active substance: Pitolisant hydrochloride) - Centralised - Yearly update - Commission Decision (2018)7974 of Mon, 26 Nov 2018

Europe -DG Health and Food Safety

22-11-2018

Buvidal (Camurus AB)

Buvidal (Camurus AB)

Buvidal (Active substance: buprenorphine) - Centralised - Authorisation - Commission Decision (2018)7879 of Thu, 22 Nov 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4651

Europe -DG Health and Food Safety

21-11-2018

EU/3/18/2082 (Takeda Pharma A/S)

EU/3/18/2082 (Takeda Pharma A/S)

EU/3/18/2082 (Active substance: 5-{(1R,2R)-2-[(cyclopropylmethyl)amino]cyclopropyl}-N-(tetrahydro-2H-pyran-4-yl)thiophene-3-carboxamide monohydrochloride) - Orphan designation - Commission Decision (2018)7791 of Wed, 21 Nov 2018 European Medicines Agency (EMA) procedure number: EMA/OD/040/18

Europe -DG Health and Food Safety

13-11-2018

EU/3/17/1836 (Zogenix GmbH)

EU/3/17/1836 (Zogenix GmbH)

EU/3/17/1836 (Active substance: Fenfluramine hydrochloride) - Transfer of orphan designation - Commission Decision (2018)7576 of Tue, 13 Nov 2018 European Medicines Agency (EMA) procedure number: EMA/OD/233/16/T/01

Europe -DG Health and Food Safety

13-11-2018

EU/3/13/1219 (Zogenix GmbH)

EU/3/13/1219 (Zogenix GmbH)

EU/3/13/1219 (Active substance: Fenfluramine hydrochloride) - Transfer of orphan designation - Commission Decision (2018)7575 of Tue, 13 Nov 2018 European Medicines Agency (EMA) procedure number: EMA/OD/140/13/T/01

Europe -DG Health and Food Safety

1-11-2018

Dexdomitor (Orion Corporation)

Dexdomitor (Orion Corporation)

Dexdomitor (Active substance: dexmedetomidine hydrochloride) - Centralised - Yearly update - Commission Decision (2018)7380 of Thu, 01 Nov 2018

Europe -DG Health and Food Safety

31-10-2018

Evista (Daiichi Sankyo Europe GmbH)

Evista (Daiichi Sankyo Europe GmbH)

Evista (Active substance: Raloxifene hydrochloride) - Centralised - Yearly update - Commission Decision (2018)7342 of Wed, 31 Oct 2018

Europe -DG Health and Food Safety

26-9-2018

Sileo (Orion Corporation)

Sileo (Orion Corporation)

Sileo (Active substance: Dexmedetomidine hydrochloride) - Centralised - Yearly update - Commission Decision (2018)6325 of Wed, 26 Sep 2018

Europe -DG Health and Food Safety

10-8-2018

Brinavess (Correvio)

Brinavess (Correvio)

Brinavess (Active substance: vernakalant hydrochloride) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5523 of Fri, 10 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/1215/T/31

Europe -DG Health and Food Safety

6-8-2018

Bosulif (Pfizer Europe MA EEIG)

Bosulif (Pfizer Europe MA EEIG)

Bosulif (Active substance: Bosutinib) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5372 of Mon, 06 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2373/T/32

Europe -DG Health and Food Safety

30-7-2018

Segluromet (Merck Sharp and Dohme B.V.)

Segluromet (Merck Sharp and Dohme B.V.)

Segluromet (Active substance: ertugliflozin / metformin hydrochloride) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5103 of Mon, 30 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4314/T/2

Europe -DG Health and Food Safety

30-7-2018

Ceplene (Noventia Pharma Srl)

Ceplene (Noventia Pharma Srl)

Ceplene (Active substance: Histamine dihydrochloride) - Centralised - Renewal - Commission Decision (2018)5116 of Mon, 30 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/796/R/36

Europe -DG Health and Food Safety

23-7-2018

Optruma (Eli Lilly Nederland B.V.)

Optruma (Eli Lilly Nederland B.V.)

Optruma (Active substance: Raloxifene hydrochloride) - Centralised - Yearly update - Commission Decision (2018)4893 of Mon, 23 Jul 2018

Europe -DG Health and Food Safety

12-7-2018

Econor (Elanco Europe Ltd)

Econor (Elanco Europe Ltd)

Econor (Active substance: Valnemulin hydrochloride) - Centralised - Yearly update - Commission Decision (2018)4580 of Thu, 12 Jul 2018

Europe -DG Health and Food Safety

11-7-2018

Ariclaim (Eli Lilly Nederland B.V.)

Ariclaim (Eli Lilly Nederland B.V.)

Ariclaim (Active substance: duloxetine hydrochloride) - Centralised - Withdrawal - Commission Decision (2018)4515 of Wed, 11 Jul 2018

Europe -DG Health and Food Safety

5-7-2018

Scientific guideline:  Draft pegylated liposomal doxorubicin hydrochloride concentrate for solution 2 mg/ml product-specific bioequivalence guidance, draft: consultation open

Scientific guideline: Draft pegylated liposomal doxorubicin hydrochloride concentrate for solution 2 mg/ml product-specific bioequivalence guidance, draft: consultation open

This document provides product-specific guidance on the demonstration of the bioequivalence of pegylated liposomal doxorubicin hydrochloride concentrate for solution 2 mg/ml.

Europe - EMA - European Medicines Agency

3-7-2018

Efficib (Merck Sharp and Dohme B.V.)

Efficib (Merck Sharp and Dohme B.V.)

Efficib (Active substance: sitagliptin / metformin hydrochloride) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018) 4254 of Tue, 03 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/896/T/90

Europe -DG Health and Food Safety

3-7-2018

Ristfor (Merck Sharp and Dohme B.V.)

Ristfor (Merck Sharp and Dohme B.V.)

Ristfor (Active substance: sitagliptin / metformin hydrochloride) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018) 4249 of Tue, 03 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/1235/T/77

Europe -DG Health and Food Safety

3-7-2018

Velmetia (Merck Sharp and Dohme B.V.)

Velmetia (Merck Sharp and Dohme B.V.)

Velmetia (Active substance: sitagliptin / metformin hydrochloride) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018) 4252 of Tue, 03 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/862/T/93

Europe -DG Health and Food Safety

3-7-2018

Janumet (Merck Sharp and Dohme B.V.)

Janumet (Merck Sharp and Dohme B.V.)

Janumet (Active substance: sitagliptin / metformin hydrochloride) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018) 4251 of Tue, 03 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/861/T/90

Europe -DG Health and Food Safety

29-6-2018

EU/3/18/2028 (BioCryst UK Ltd)

EU/3/18/2028 (BioCryst UK Ltd)

EU/3/18/2028 (Active substance: (R)-1-(3-(aminomethyl) phenyl)-N-(5-((3-cyanophenyl)(cyclopropylmethylamino)methyl)-2-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide dihydrochloride) - Orphan designation - Commission Decision (2018)4173 of Fri, 29 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/003/18

Europe -DG Health and Food Safety

14-6-2018

Kuvan (BioMarin International Limited)

Kuvan (BioMarin International Limited)

Kuvan (Active substance: sapropterin dihydrochloride) - Centralised - Yearly update - Commission Decision (2018)3859 of Thu, 14 Jun 2018

Europe -DG Health and Food Safety

13-6-2018

Suboxone (Indivior Europe Limited)

Suboxone (Indivior Europe Limited)

Suboxone (Active substance: buprenorphine / naloxone) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)3632 of Wed, 13 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/697/T/38

Europe -DG Health and Food Safety

12-6-2018

EU/3/10/811 (Celgene Europe B.V.)

EU/3/10/811 (Celgene Europe B.V.)

EU/3/10/811 (Active substance: N-tert-butyl-3-[(5-methyl-2-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}pyrimidin-4-yl)amino] benzenesulfonamide dihydrochloride monohydrate) - Transfer of orphan designation - Commission Decision (2018)3809 of Tue, 12 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/092/10/T/03

Europe -DG Health and Food Safety

12-6-2018

EU/3/10/810 (Celgene Europe B.V.)

EU/3/10/810 (Celgene Europe B.V.)

EU/3/10/810 (Active substance: N-tert-butyl-3-[(5-methyl-2-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}pyrimidin-4-yl)amino] benzenesulfonamide dihydrochloride monohydrate) - Transfer of orphan designation - Commission Decision (2018)3808 of Tue, 12 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/084/10/T/03

Europe -DG Health and Food Safety